FDA Brief

Warning letters Drugs

FDA warning letter to

LyfeUnit / www.lyfeunit.com

High riskIssued Jun 23Posted Jul 7Center for Drug Evaluation and Research (CDER)

FDA warns LyfeUnit website for selling unapproved, misbranded ketamine vials to U.S. consumers.

What happened

FDA reviewed www.lyfeunit.com on February 27, 2026, and found it offering ketamine 500mg/10ml vials marketed as “Mental Health Treatments.” FDA said the product is an unapproved new drug and is misbranded because its labeling lacks adequate directions for use and it is offered without a prescription.

What FDA found

  1. The website sold ketamine 500mg/10ml vials without an FDA-approved drug application.

    FD&C Act sections 301(d) and 505(a) (21 U.S.C. 331(d), 355(a))
  2. The ketamine product's labeling did not give adequate directions for safe use by a layperson.

    FD&C Act section 502(f)(1) (21 U.S.C. 352(f)(1))
  3. The website offered a prescription drug without requiring a prescription from a licensed practitioner.

    FD&C Act sections 503(b)(1) and 301(k) (21 U.S.C. 353(b)(1), 331(k))
  4. The website introduced misbranded drugs into interstate commerce.

    FD&C Act section 301(a) (21 U.S.C. 331(a))

What FDA wants

FDA asks LyfeUnit to stop offering any unapproved and misbranded drugs for sale to U.S. consumers and to respond within 15 business days with corrective steps, preventive steps, and supporting documents.

Who should pay attention

  • online sellers of ketamine or psychiatric drugs
  • telehealth and mental health platforms that mention ketamine
  • buyers and importers of foreign-labeled injectable drugs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk
  4. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk